Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - memantine hydrochloride 20 mg - eq. memantine 16,62 mg - film-coated tablet - 20 mg - memantine hydrochloride 20 mg - memantine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - memantine hydrochloride 10 mg - eq. memantine 8,31 mg - film-coated tablet - 10 mg - memantine hydrochloride 10 mg - memantine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - memantine hydrochloride 20 mg - eq. memantine 16,62 mg - film-coated tablet - 20 mg - memantine hydrochloride 20 mg - memantine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - memantine hydrochloride 10 mg - eq. memantine 8,31 mg - film-coated tablet - 10 mg - memantine hydrochloride 10 mg - memantine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - memantine hydrochloride 20 mg - eq. memantine 16,62 mg - film-coated tablet - 20 mg - memantine hydrochloride 20 mg - memantine

Israel - English - Ministry of Health

teva israel ltd - memantine hydrochloride - film coated tablets - memantine hydrochloride 10 mg - memantine - treatment of patients with moderate to severe alzheimer’s disease.

Israel - English - Ministry of Health

teva israel ltd - memantine hydrochloride - film coated tablets - memantine hydrochloride 20 mg - memantine - treatment of patients with moderate to severe alzheimer’s disease.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 10 mg - memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the alzheimer's type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine hydrochloride during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated po

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - memantine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; microcrystalline cellulose; lactose monohydrate; magnesium stearate; macrogol 6000 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology and precautions).

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

jazeera pharmaceutical industries (jpi), saudi arabia - memantine hydrochloride - tablet, film coated - 10 mg